From Pulse 2.0 · Amit Chowdhry · · 40s
Georgia State University Finds Metabolite Compounds for Ulcerative Colitis
New compounds from Georgia State University show promise for ulcerative colitis treatment.
In brief
New compounds from Georgia State University show promise for ulcerative colitis treatment. Georgia State University researchers identified metabolite-inspired compounds that reduce inflammation in ulcerative colitis models. Originally reported by Pulse 2.0.
New Compounds Show Promise
Georgia State University researchers identified two metabolite-inspired compounds that showed enhanced anti-inflammatory activity in ulcerative colitis models.
Compounds Improved Disease Measures
MLY2 and MLY8 restored colon length and reduced fecal lipocalin-2 in mouse colitis models.
Compounds Suppressed Inflammation
MLY2 and MLY8 suppressed inflammatory cytokine production more effectively than M13 in human colon tissue.
Metabolites as Drug Starting Points
Biologically active phase II metabolites could serve as underused starting points for new anti-inflammatory drugs.
“This work shows that modifying the chemical structure of a biologically active phase II metabolite can be a productive strategy for discovering new anti-inflammatory drug candidates. The findings provide a foundation for follow-up studies, suggesting that biologically active phase II metabolites may represent underutilized scaffolds for medicinal chemistry optimization in inflammatory disease.”
What to remember
Georgia State University researchers identified metabolite-inspired compounds that reduce inflammation in ulcerative colitis models.
